Mednet Logo
HomeMedical OncologyQuestion

Which regimen do you prefer for patients with newly diagnosed DLBCL that are not candidates for doxorubicin secondary to low ejection fraction?

2
1 Answers
Mednet Member
Mednet Member
Medical Oncology · Riverside Methodist Hospitals/OhioHealth

I like to use R-CEOP per Vancouver experience. Had very good results with it and is very well tolerated. I sometimes use it also in frail older patients who have normal EF. Etoposide substitutes doxorubicin in regimen: 50 mg/m2 on D1 and 100 mg/m2 PO on days 2-3 and can also give peg filgrastim on D...

Register or Sign In to see full answer

Which regimen do you prefer for patients with newly diagnosed DLBCL that are not candidates for doxorubicin secondary to low ejection fraction? | Mednet